BiotechTV - News

She describes The Bank's goal of supporting life sciences in Scotland and making a societal impact, how it aims to co-invest with likeminded investors. Plus, examples of investments such as Elasmogen and PneumoWave.

Professor Cullis, one of the original pioneers of LNPs and co-founder of 11 biotechnology companies, describes the challenge of successfully using lipid nanoparticles to deliver payloads to places outside of the liver. Jay Kulkarni, a former postdoc of his who is co-founder and CSO of the company, describes the 'one-stop-shop' capabilities of NanoVation, which has already led to a partners...

CEO Ken Macnamara describes the science behind this idea and discusses recently presented preclinical data. He highlights the lead program for glioblastoma and plans for the future, and also explains how he believes a patient sample biobank Trogenix has built is key to the company's success in research.

Andrew McNeill, Managing Partner of St. Andrews based Eos Advisory, introduces us to the firm and some portfolio companies including Dxcover and Laverock Therapeutics.

Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.

Founder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for the long-term. She describes the lead investments: a PARG inhibitor, GPR68 small molecules, and a GTPase inhibitor.

CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.

Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.

Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been built and the work that takes place at the centre, including founding companies like Amphista Therapeutics. Plus, his take on the field more broadly and targets that researchers are going after.

Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their pharma partnerships and licenses, and cases where independent biotech companies have spun out of the work.

He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU), the Drug Discovery Unit, the soon-to-open Innovation Hub, and more.

Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25% higher recovery rate compared to standard treatment.

He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus, comments on Structure Therapeutics, Corbus, Skye Bioscience, Zealand, Viking, Altimmune, Terns, and BioAge Labs.

Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vector delivery capabilities, and improving the yield and lowering the cost of future treatments, that is possible with the latest generation of gene therapy.

CEO Antony Mattessich describes the company's approach and the advantages he believes it has over other TPD. Plus, the lead program targeting BRD9, and how the company thinks about partnerships going forward.

Co-Founder and CEO Sam Windsor describes the rationale for using AI to focus more on tox, not efficacy, and gives and example of a drug the company has already in-licensed from a pharma company. Plus, what today's raise will enable the company to do.

CEO Richard Mason describes the company's philosophy, and covers programs such as a FGF21/GLP-1 that was recently licensed from a Chinese partner, an IL18, ZIP12, and more.

He shares his take on biotech and discusses Alkermes, Tekada, Centessa, Jazz, Biogen, Stoke, Alnylam, BridgeBio, Xenon, and more.

CEO Pascal Hickey introduces us to the company and describes the scale up work Aravax is doing with vendors for its lead peanut allergy program, while CSO Sara Prickett explains how the peptide approach aims to teach T-cells to correct allergies while not setting off allergic inflammation that today's therapies do.

CEO David Apelian describes the importance of choosing the right strain for the right type of cancer, and discusses the company's lead program for ovarian cancer.

Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.

He describes the design of the global pivotal study, which will be initiating soon, why Stoke chose Biogen as a partner, and how today's non-dilutive financing could help Stoke realize its goal to be a platform company.

Bo Cumbo describes the efficacy biomarkers and safety profile they are seeing, and explains why he believes the cascade of observations from microdystrophin expression down to muscle integrity are important and pointed in the right direction. Plus, why the company secured a $200M raise before releasing the data publicly.

Sponsored Content: She describes what appealed to her about Allucent when she took the CEO job in July of last year, and highlights the company's regulatory expertise, nimbleness, consulting and strategy skills, modeling and biostatistics knowhow, and more.

Ryan is based in the Bay Area, and will will be covering AI news there on the ground and virtually worldwide for BiotechTV.